GFM
IBRX icon

GF Fund Management’s ImmunityBio IBRX Stock Holding History

GF Fund Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$170K Buy
22,120
+2,765
+14% +$18.9K ﹤0.01% 298
2025
Q4 		$38.3K Sell
19,355
-982
-5% -$2.23K ﹤0.01% 429
2025
Q3 		$50K Buy
20,337
+2,494
+14% +$6.42K ﹤0.01% 395
2025
Q2 		$47.1K Hold
17,843
– – ﹤0.01% 419
2025
Q1 		$53.7K Buy
17,843
+3,211
+22% +$9.73K ﹤0.01% 414
2024
Q4 		$37.5K Buy
+14,632
New +$61K ﹤0.01% 418

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

GF Fund Management's IBRX Position: Q1 2026 in Review

GF Fund Management increased its ImmunityBio (IBRX) stake by 14% in Q1 2026, buying an estimated $18.9K and bringing the position to 22,120 shares worth $170K. The position accounts for ﹤0.01% of the portfolio, ranked #298.

GF Fund Management first reported a position in IBRX in Q4 2024 and has held it in 6 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • GF Fund Management held 22,120 shares of ImmunityBio worth $170K as of Q1 2026.
  • GF Fund Management bought 2,765 ImmunityBio shares in Q1 2026, an estimated $18.9K.
  • ImmunityBio made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #298 holding.
  • GF Fund Management first reported a position in ImmunityBio in Q4 2024 and has held it in 6 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.